Interestingly, several studies reported that the LOF mutation rather than other types of VHL alteration showed meaningful relationship with survival outcome and response to VEGF-targeted therapy in patients with RCC [15–17, 20, 21]. The gene discussed is VEGFA; the disease is renal cell carcinoma.